Richard Zeifman

Assistant Professor of Psychology and Director of PATH Lab

Data updated

Papers

23 publications

Trials

0 clinical trials

Research Footprint

Richard Zeifman appears in 23 tracked papers (2019–2026), most studied alongside Psilocybin, MDMA and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Suicidality.

Most-cited paper: Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression (222 citations).

Frequent co-authors: Robin Carhart-Harris, Hannes Kettner and David Erritzoe.

Background & Research

Dr. Richard Zeifman leads the PATH Lab at The New School, focusing on the safety and efficacy of psychedelic-assisted therapy. As a licensed clinical psychologist and researcher, he conducts clinical trials and effectiveness studies to understand how psilocybin and MDMA promote psychological flexibility and long-term recovery in patients with MDD, cancer-related distress, and PTSD.

Key Impact

Investigates mechanisms of change in psychedelic therapy for depression, trauma, and suicidality.

23

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

54 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinMDMAAyahuascaLSDDMTPlacebo

Topics

Depressive DisordersAnxiety DisordersSuicidalityMajor Depressive Disorder (MDD)PTSDPalliative & End-of-Life DistressPersonality DisordersSubstance Use Disorders (SUD)Interpersonal Functioning & Social ConnectednessHealthy VolunteersNeuroimaging & Brain MeasuresPersonality & Trait FactorsBorderline Personality Disorder (BPD)Alcohol Use Disorder (AUD)SchizophreniaPublic Health, Prevention & Behaviour ChangeMicrodosingSafety & Risk ManagementChronic PainHealth Economics & ReimbursementEating DisordersAdolescentsBipolar DisorderObsessive-Compulsive Disorder (OCD)Treatment-Resistant Depression (TRD)Set & Setting

Top Collaborators

Affiliations

Institutions, companies, and organisations Richard Zeifman is associated with.

The New School for Social Research

The New School for Social Research is the graduate division of The New School in New York City, offering advanced degrees and research in the social sciences, philosophy, and history. It is known for progressive, interdisciplinary scholarship and a history rooted in the University in Exile that supported scholars fleeing fascism in the 1930s.

View stakeholder →

Centre for Addiction and Mental Health

hospital

The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health teaching hospital, located in Toronto, Ontario. CAMH is a major hub for psychedelic research in Canada, running trials on psilocybin, MDMA, and ketamine across a range of psychiatric indications.

View stakeholder →

Imperial College London

academic

The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).

View stakeholder →

Toronto Metropolitan University

academic

Toronto Metropolitan University (formerly Ryerson University) is a public research university in downtown Toronto, Canada. Its psychology, health science, and social science researchers participate in clinical studies on psychedelic-assisted therapy, with faculty investigating the effects of psilocybin and other compounds on mental health outcomes in clinical and community populations.

View stakeholder →